One of the main histological hallmarks observed in the cortex of Alzheimer's disease-affected patients is the senile plaque, a proteinaceous deposit that derives mainly from the overproduction of a 39±43 amino-acid-containing peptide called b-amyloid (Ab). The most striking evidence that Ab overproduction is intimately linked to Alzheimer's disease pathology comes from observations that all but one (Ancolio et al. 1999) of the pathological mutations located on the genes responsible for early onset aggressive forms of the disease, lead to an increase in Ab production and, particularly, in the production of the more readily aggregable 42-amino-acid-long species (Van Broeckhoven 1995; Hutton and Hardy 1997) . Whether Ab is, per se, the etiological cause of the disease, or whether it behaves as an intermediate effector of a pathological cascade of events is still a matter of discussion. However, whatever the case, it remains clear that Ab derives from its precursor, the b-precursor protein, by enzymatic digestion by so-called b-and g-secretases, two proteolytic activities responsible for the generation of the N-and C-termini of Ab, respectively (Selkoe 1991; Checler 1995) . As the inhibition of these two activities is theoretically the easiest possibility of slowing down or blockading Ab-mediated Alzheimer neuropathology, several teams have targeted the b-and g-secretases for identi®cation and characterization. It is now generally believed that an unusual membrane-bound aspartyl protease (BACE; b-site APP cleaving enzyme, or memapsin2 or Asp2) is a b-secretase (Hussain et al. 1999; Sinha et al. 1999; Vassar et al. 1999; Yan et al. 1999; Lin et al. 2000) . Concerning the elusive g-secretase, several groups suggest that presenilins could act as the genuine g-secretase, a hypothesis that is disputed by others. Here, we will present some objective experimental and theoretical arguments that lead us to argue against a direct role of presenilins as proteases.
Presenilins 1 and 2 are homologous proteins that most likely play a central role in Alzheimer's pathology. First, when mutated, these proteins are associated with early onset forms of the disease and, indeed, appear responsible for most of the autosomal dominant familial cases of the disease (Van Broeckhoven 1995; Hutton and Hardy 1997) . Similar to all but one of the mutations on bAPP, mutations on presenilins trigger the increased production of Ab42, and speci®cally increase the Ab42 : total-Ab ratio (Checler 1999a) . It is easy to envisage that mutations in bAPP, all located near the g-secretase-targeted sequence, can introduce modi®cations of the recognition/catalytic parameters of g-secretase for bAPP. Therefore, this may explain the phenotypical alteration of bAPP maturation at the g-secretase site. At this stage, it is more dif®cult to conceive how mutations in presenilins, which appear widely distributed within the serpentine sequence of presenilins, i.e. in putative transmembrane domains as well as in the hydrophilic domains, could lead to the same selective increase in production of Ab42. Before there was any de®nite explanation for these observations, this ®nding alone indicated that there was likely to be a control of g-secretase-mediated bAPP maturation, mediated either directly or indirectly, by presenilins.
An important breakthrough in the elucidation of this bAPP/presenilins link came from the deletion of presenilin genes. Bart De Strooper and colleagues elegantly demonstrated that the knock-out of the presenilin 1 gene led to drastic reduction in the g-secretase-mediated cleavage of bAPP (De Strooper et al. 1998) . The residual secretion of Ab40/42 in presenilin 1 knock-out cells appeared likely to be caused by the contribution of endogenous presenilin 2, as the double knock-out of both presenilins 1 and 2 fully abolished Ab secretion (Herreman et al. 2000; Zhang et al. 2000b ). These observations, however, did not elucidate the mechanism by which presenilins in¯uence g-secretasemediated bAPP cleavage.
Interestingly, the knock-out of the presenilin 1 gene is lethal and leads to drastic abnormalities during embryogenesis, particularly in the caudal region as a result of skeletal defects (Shen et al. 1997; Davis et al. 1998; Donoviel et al. 1999) . Strikingly, this phenotype appears reminiscent of that observed when the gene for Notch-1, a transmembrane protein involved in cell fate decision, is deleted. The similarity between the presenilin-1 and Notch-1 deletion phenotypes is consistent with earlier genetic evidence suggesting that presenilins correspond to the C. elegans homolog sel-12, which is involved in the signalling mediated by lin-12, the nematode counterpart of Notch (Levitan and Greenwald 1995; Baumeister et al. 1997) . Notch signalling is dependent upon a proteolytic cleavage occurring inside the plasma membrane, close to the inner side of the membrane facing the cytoplasm (Schroeter et al. 1998) . This cleavage liberates an intracellular fragment, the Notch intracellular domain (NICD), which translocates into the nucleus where it mediates Notch function. The knockout of the presenilin gene also leads to the impairment of NICD production (De Strooper et al. 1999) , thereby probably explaining the observed dramatic embryogenic alterations.
Taken together, these ®ndings show that presenilins are associated with two cellular phenotypes, Ab and NICD production, which involve key proteolytic events. This conclusion led several teams to suggest that both g-secretase-mediated cleavage of bAPP and NICD production could be a result of the same activity, and the most natural' hypothesis was that this activity could correspond to the presenilins themselves. The most direct lines of evidence supporting this possibility, based on biochemical, pharmacological and mutational approaches, were the following: (1) presenilins co-purify with g-secretase-like activity in a high-molecular-weight complex (Li et al. 2000b) ; (2) peptide-based transition state aldehyde inhibitors prevent Ab and NICD production and interact with presenilins after cross-linking (Esler et al. 2000; Li et al. 2000a; Seiffer et al. 2000) ; (3) mutation of two critical aspartyl residues prevents presenilin endoproteolysis and abolishes both Ab and NICD production Wolfe et al. 1999; Berezovska et al. 2000; Capell et al. 2000; Kimberly et al. 2000) . It has therefore been strongly suggested that presenilins could correspond to a novel type of autocatalytically activated aspartyl protease.
The mutation paradox
The hypothesis that presenilins are the genuine g-secretases faces several theoretical and conceptual problems, and careful examination of some of the studies cited above leads to somewhat contradictory results. The very ®rst report on presenilins as molecular entities bearing catalytic potential, came from a study by Wolfe and colleagues that indicated that the substitution of aspartyl residues 257 and 385 (by alanines) in presenilin 1 prevented g-secretase-mediated cleavage of bAPP . Furthermore, it was reported that the endoproteolytic breakdown of presenilin 1 [a well-known cleavage that leads to N-and C-terminal presenilin 1 fragments, thought to associate and form the biologically active entity (for a review see (Checler 1999b)] was also abolished by mutation of the aspartyl residues . It was therefore suggested that presenilin 1 could be a novel transmembrane enzyme, the prototypic member of a novel class of aspartyl proteases, and that it could be activated by autocatalysis. The di-aspartyl residues involved in the catalytic site were proposed to be located in transmembrane domains 6 and 7, totally embedded in the membrane hydrophobic environment. We will not discuss here the fact that this model revolutionizes the concept of catalysis by implying the presence of water in a very unfriendly hydrophobic environment. Indeed, the localization of aspartyl 385 of presenilin 1 in the membrane has not been clearly demonstrated. However, it is important to emphasize here a theoretical concept about acidic proteases. In all acidic proteases [it should be noted here that a recent paper indicated that presenilin-mediated g-secretase cleavage is sensitive to pepstatin , as are all`classical' acidic proteases (Davies 1990 )], the two aspartyl residues behave as an acid±base couple that require one protonated and one deprotonated aspartyl moiety. This means that mutation of one of the aspartyl residues should be suf®cient to fully abolish catalysis. Nevertheless, it has been reported that mutation of the aspartate 257 residue of presenilin 1 abolishes NICD production without affecting Ab recovery . This observation is hard to reconcile with the hypothesis of a di-aspartyl group directly involved in the catalytic events responsible for Ab and NICD production.
The ability to discriminate between presenilin-mediated Ab and NICD production was further demonstrated by Kulic and colleagues (Kulic et al. 2000) who introduced arbitrary mutations at position 286 of presenilin 1 (a welldescribed position responsible for familial forms of Alzheimer's disease), and showed that Ab42 recovery was greatly enhanced whereas NICD production was impaired (Kulic et al. 2000) . The easiest way to reconcile these interesting data with other results is to envisage presenilins acting upstream of g-secretase. Alternatively, to stick to the presenilin/protease hypothesis, it would be necessary to consider that presenilins would bear several catalytic sites selectively responsible for Ab-or NICD formation. However, in this case, it would be dif®cult to understand the results from the mutagenesis studies that show abolition of the overall catalytic potential of presenilin 1/2 for both Notch and bAPP by mutating only the C-terminal aspartyl residue.
Another important result has arisen from a recent study showing that a glycine residue adjacent to aspartate 385 (glycine 384, using the presenilin 1 numbering) is conserved in bacterial acidic proteases and that its mutation affects Ab and NICD recovery . What does this ®nding teach us? This study demonstrates that mutations of residues other than the aspartyls can lead to the same phenotypic alterations. Here, the important point is that the nature itself of the mutated residue, i.e. a glycine, precludes the possibility of a direct contribution to catalysis, as glycine residues lack a side chain, an obligate structural element needed to contribute to the polarization of the scissile bond. It can be argued that this glycine residue contributes to the substrate binding/recognition site. It remains clear that mutating a residue that is not directly involved in catalysis can mimic the effect of the aspartyl residue mutations. As a corollary, the phenotypic alteration observed when mutating aspartyl residues is not suf®cient per se to demonstrate a direct participation in catalysis.
What could we propose as a mechanism underlying the observed effect of the glycine mutation? It could be argued that this residue occurs in a functionnally strategic structural zone of presenilins. In this context, it is noteworthy that mutation of this glycine is particularly ef®cient in decreasing Ab and NICD production when a proline residue (an amino-acid that theoretically induces structural changes in the polypeptide backbone) or a lysine (that adds an additional`charge') is introduced in the sequence , i.e. when structural perturbations are likely to occur. In contrast, the substitution of the glycine residue by an aliphatic alanine drastically increased Ab recovery . This Gly 3 Ala transformation in fact corresponds to a natural familial Alzheimer's disease (FAD)-linked mutation known to drastically exacerbate Ab42 production.
The latter point leads us to a very general statement, that it is very striking that most of the FAD mutations on presenilins lead to increased production of Ab, speci®cally Ab42. As these mutations are widely distributed all along the presenilin sequence, i.e. in transmembrane domains as well as in hydrophilic structures, it is hard to envisage that all presenilin mutations similarly affect bAPP catalysis. Furthermore, a recent paper indicated that a mutation at cysteine 92 of presenilin 1, as expected, increased Ab42 but impaired Notch/Lin12 signalling in C. elegans (Zhang et al. 2000a) . A systematic assessment of the effects of a series of FAD-mutations on both Ab and NICD productions should shed light on a further discrimination between these two paradigms.
The pharmacological paradox
Studies aimed at delineating the sensitivity of Ab-generating activities into various classes of inhibitors would per se deserve a review. Among these studies, it is particularly interesting to note a report suggesting that the 40-and 42-residue species of Ab could be generated by distinct g-secretases (Citron et al. 1996) that are differentially sensitive to MDL28170, an aldehyde inhibitor formely characterized as a potent calpain blocker (Mehdi 1991 ). This observation is puzzling. Theoretically, an enzyme can hydrolyse a given substrate at distinct sites with various af®nities. This is re¯ected by the resulting ratio of the various catabolites. In the coupling of presenilins/APP, this possibility would explain the fact that a 9 : 1 (Ab40/42) ratio is observed in many studies. However, an inhibitor acting on a single catalytic site should affect the absolute amounts of the products generated but not the ratio of their production, as was reported for MDL28170 (Citron et al. 1996) . This theoretical consideration, although a very basic enzymologic statement, can be seen by itself as a de®nite argument against the presenilins/secretase hypothesis.
Recent studies on the design of peptide-based transition state analog inhibitors [referred to as MW167 (Wolfe et al. 1998) or commercially available under the nomenclature DFK167] have described these pharmacological agents as potent inhibitors of Ab production (Wolfe et al. 1998; De Strooper et al. 1999) and Notch cleavage (De Strooper et al. 1999; Berezovska et al. 2000) . If presenilins are autocatalytically activated secretases, these agents should be expected to prevent presenilin endoproteolysis. We recently established that DFK167 is unable to block endoproteolysis of endogenous or overexpressed presenilin (Petit et al. 2000) , a paradigm that was not examined by others (Wolfe et al. 1998) . These data agree well with another study showing that an engineered uncleavable presenilin, in which a pathological mutation had been introduced, still triggers increased production of Ab42 (Steiner et al. 1999) . Thus, despite previous reports , by pharmacological and mutagenesis approaches, it is clearly possible to distinguish between presenilin endoproteolysis and Ab-generation.
Another problem for the presenilins/secretase hypothesis arises from our recent study establishing that novel nonpeptidic inhibitors can fully block the production of secreted Ab40 and Ab42 from cells expressing wild-type bAPP, and increase the recovery of endogenous C83 and C99 C-terminal fragments of bAPP (derived from a-and b-secretase cleavage, respectively). In this study, we found that endoproteolysis of presenilin and Ab generation are two cellular events that can be dissociated, as presenilin cleavage was not affected by our inhibitors. More strikingly, our inhibitors did not affect NICD production (Petit et al. 2000) . It should be emphasized here that we were monitoring the direct production of NICD and not the ®nal phenotype associated with NICD that could have been modulated downstream to the primary catalytic event, along the cascade of cellular intermediates. Here again, in classical enzymology, the enzyme/inhibitor complex is characterized by a unique inhibition constant (K i ) value, and this constant The multiple paradoxes of presenilins 1623 does not vary according to the type of substrate, even if a single enzyme (in our case g-secretase/Notch cleaving activity) can display various af®nities (K m ) for its various substrates. Therefore, mutational (aspartate 257 of presenilin 1) or pharmacological discrimination (our inhibitors) approaches converge to cast a shadow over the hypothesis of a presenilin enzymatic entity.
Independent studies have indicated that it is possible to cross-link radiolabeled inhibitors to presenilins and their fragments (Esler et al. 2000; Li et al. 2000a; Seiffer et al. 2000) . It should be noted that because of methodological problems, probably related to the permeability of the inhibitors and the relatively low af®nity for the`enzyme', some of the cross-linking experiments were performed in vitro on cell extracts (Li et al. 2000a) , and, in this case, whether the probes had reached their`real' endogenous target remains questionable. Another study described crosslinking experiments in cell lysates and isolated microsomes as well as in situ, in living cells (Esler et al. 2000) . However, it should be noted that the demonstration of the speci®city of the covalent binding, i.e. the prevention of the labeling with unlabeled probe, was only partial in microsomes and was not documented in living cells (Esler et al. 2000) . Finally, it is relatively dif®cult to envisage how an identical probe only differing by the location of the cross-linking group, could alternately label either the N-or the C-terminal fragment of presenilins (Li et al. 2000a) . When considering the proposed model of a transmembrane`hydrophilic' pore formed by the direct interaction between N-and C-terminal presenilin fragments, it is dif®cult to reconcile this proposition with the very small size of the inhibitor that would have to act as à hook' able to ®sh out both fragments. This last point of my argument can be still debated, as the putative structural model of presenilin organization in the membrane still awaits demonstration. One cannot de®nitely rule out the possibility that the N-and C-terminal fragments are so closely associated that cross-linking the two subunits would remain possible.
The spatial and`cleaved site' paradoxes
Not so long ago, we would have taken as a very strong argument the`spatial paradox' (a concept that is not ours!) concerning the cellular sites of Ab and NICD production. It was previously thought that presenilins were proteolytically processed in the early secretory pathway, probably in the endoplasmic reticulum, and that no presenilin-like immunoreactivity was present in the plasma membrane (for a review see Checler 1999b), a cell compartment thought to be the site of NICD production. Now, several papers have provided evidence that presenilin immunoreactivity could be associated with the plasma membrane. Although this ®nding is still debated, the observation potentially resolves a problem caused by the difference between the subcellular localization of Notch and presenilin. However, let's consider that presenilins are indeed located at the endoplasmic reticulum/Golgi (where most of Ab is generated) and also at the plasma membrane level (where NICD is produced). This means that an identical activity would occur in cell compartments displaying distinct physicochemical features. Signi®cantly, this would imply that presenilins would be able to cleave distinct substrates ef®ciently in both very acidic or virtually neutral pH environments. This would be a totally novel feature for an aspartyl protease, because, as stated above, an absolute requirement for functional acidic proteases is the presence of one ionised and one protonated lateral chain of the two aspartyl residues (Pearl 1987) . This explains why most acidic proteases display a maximal activity at a pH close to the pK value of the aspartyl carboxyl, i.e. around pH 4. In the environment of the plasma membrane, i.e. close to neutral pH, the two aspartyl residues would be in the ±COO _ deprotonated forms. This chemical state would preclude any possible hydrogen bonding of the water molecule to the active aspartyl residues, an intermediate step necessary for further attack of the carbonyl carbon of the scissile bond of substrates.
More striking is the nature and intramembrane localization of peptide bonds targeted by g-secretase and Notchcleaving enzymes. There is no apparent amino acid sequence around the cleaved bonds that could be seen as a putative consensus recognized sequence. It is true that this is not an unusual feature for proteolytic activities, but very often, it is compensated for by another structural element. The apparent speci®city could be driven by substrate recognition and accommodation within the catalytic site of the enzyme, which would be dependent upon the topological con®guration of the enzyme near to its substrate. As an example, membrane-bound a-secretase clearly cleaves a number of substrates at very distinct peptide bonds, but always at the same distance from the membrane (Sisodia 1992) , probably because there exists a molecular adaptation driven by the enzyme/substrate topology. It is not anecdotal to emphasize the fact that presenilins do not fall into any of these situations. Thus, not only are the sequences targeted totally unrelated, but the intramembrane site of cleavage of bAPP (middle of the membrane) is distinct from Notch cleavage (close to the inner lea¯et of the plama membrane).
Is there an alternative explanation?
The most likely alternative explanation is that presenilins behave as molecular chaperones of bAPP, g-secretase or both. If presenilins bind to bAPP upstream of all secretase activities, this could explain why presenilin 1 was reported to also modulate the constitutive (Ancolio et al. 1997 ) and regulated (Murphy et al. 2000) the production of the a-secretase-derived secreted APP fragment (sAPPa). Many proteins have been shown unambiguously to interact directly with presenilins (for reviews see Checler 1999a,b) . This leads to theoretical considerations. Chaperon proteins interact ®rmly with their binding partners because of their very high af®nity (low nanomolar range). These af®nities (or the dissociation constant, K d ) explain why it is possible to co-immunoprecipitate two interacting cellular partners. In contrast, the af®nity of proteases for their substrates is usually more than one thousand-fold lower (the Michaelis constant, K m , is in the 1±10 mm range). This explains why, to our knowledge, there is no example of a protease coimmunoprecipitating with its physiological substrate, as has been demonstrated for presenilin and bAPP. If the role of presenilins as a molecular transporter is privileged, it should be noted that Naruse et al. demonstrated nicely that deletion of presenilin 1 drastically impaired the neuronal intracellular transport of several proteins including bAPP ). An important communication by Dr S. S. Sisodia (at the 30th annual meeting of American Neuroscience) documented the fact that single or double aspartate 257 or 385 mutations of presenilin 1 all drastically affect bAPP traf®cking, leading to considerable accumulation of intact bAPP at the cell surface. This is obviously an important advance in the understanding of the alternative mechanistic explanations for the effect triggered by presenilin aspartyl mutations.
Provocative digressions
A few provocative issues could be raised at this stage. If presenilins are the genuine g-secretases, are they cleaving all proteins with which they interact or are they selective for bAPP? If increasing or abolishing Ab production by mutating or deleting a given protein is a good clue to suggest that such a protein is g-secretase, should we not also regard nicastrin as an additional putative candidate? Indeed, this novel protein interacts with presenilins, when mutated triggers increased production of Ab, and when inactivated by a small deletion (that could be seen as a molecular knock-out), Ab production is impaired (Yu et al. 2000) .
Conclusion
This debate would be solved if presenilin could be puri®ed to homogeneity and could be shown to display in vitro catalytic activity towards bAPP (or any other protein). Using current techniques, we are relatively pessimistic about this possibility, as transmembrane proteins are hard to solubilize, and their recovery in a detergent environment rarely allows the elimination of accompanying proteins. Particularly dif®cult in the case of presenilins is the fact that to be able to measure any catalytic function, the puri®cation procedure presumably would have to preserve the heterodimeric association of the N-and C-terminal presenilin moieties thought to mediate the biological function of the protein.
Discussions about the nature of the g-secretase are not only a fundamental or intellectual debate. The issue of whether or not presenilins are the genuine g-secretase should drive future therapeutic strategies aimed at preventing g-secretase-mediated Ab production. If the same enzyme is responsible for the release of NICD, it would be dif®cult to envisage how Notch-mediated cellular functions would not also be affected, even if studies suggested that inhibiting Ab production and Notch cleavage led to only partial impairment of Notch signalling (Berezovska et al. 2000) . Differential inhibition of Ab production and Notch function may perhaps be achieved in vitro but may be much more dif®cult to achieve in human studies.
However, if presenilins are not g-secretase, the fact that novel non-peptide inhibitors drastically inhibit Ab recovery without affecting NICD production leads me to be optimistic. This observation leaves intact a theoretical therapeutic intervention targeting the g-secretase activity without`side-effects' on cellular Notch-related functions.
